Drug intelligence / Profile preview

TAA-ADC

Development stage: Preclinical
Lead developer: SparX Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TAA-ADC is a preclinical antibody-drug conjugate (ADC) being developed by SparX Biopharmaceutical. It utilizes the proprietary Nab2 dual-payload platform, which is designed to deliver two distinct cytotoxic agents to tumor cells simultaneously. This approach aims to enhance therapeutic efficacy and potentially overcome drug resistance by employing multiple mechanisms of cell killing within a single therapeutic agent. While the specific tumor-associated antigen (TAA) targeted by this candidate has not been publicly disclosed, the drug is being developed for the treatment of various cancers as part of a platform collaboration.

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on TAA-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAA-ADC.

Explore the full profile